Mechanism of action
Atorvastatin competitively inhibits HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, the rate-limiting step in hepatic cholesterol biosynthesis.
By reducing intracellular cholesterol, hepatocytes upregulate LDL receptors on their surface, increasing the clearance of LDL cholesterol from the bloodstream. This results in decreased plasma LDL-C levels (reduction of 35–50% depending on dose).
Beyond lipid lowering, statins exert pleiotropic effects that contribute to cardiovascular benefit:
- Improved endothelial function
- Reduced vascular inflammation (decreased C-reactive protein)
- Stabilization of atherosclerotic plaques
- Decreased platelet aggregation
- Antithrombotic effects
These anti-inflammatory and vascular stabilizing properties occur independently of cholesterol reduction and contribute to the reduction in cardiovascular events.
- Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis
- Upregulation of hepatic LDL receptors increases clearance of LDL cholesterol from plasma
- Major adverse effects: myopathy/rhabdomyolysis and hepatotoxicity (elevated transaminases)
- Metabolized by CYP3A4; risk of myopathy increases with azoles, macrolides, and gemfibrozil
- Absolutely contraindicated in pregnancy (Category X) and active liver disease
- High-intensity statin (40-80 mg) lowers LDL cholesterol by ≥50 percent
- Statins modestly increase risk of new-onset diabetes but cardiovascular benefits outweigh risks
- Discontinue if CK exceeds 10 times upper limit of normal or symptomatic myopathy develops
Indications
Primary prevention
- Hyperlipidemia (elevated LDL cholesterol and total cholesterol)
- Reduction of cardiovascular risk in patients with multiple risk factors (diabetes, hypertension, smoking, family history)
Secondary prevention
- Established coronary artery disease
- Prior myocardial infarction
- Stable or unstable angina
- History of stroke or transient ischemic attack
- Peripheral arterial disease
- Prior coronary or arterial revascularization
Special populations
- Diabetic patients aged 40–75 years (primary prevention)
- Patients with LDL cholesterol ≥190 mg/dL (familial hypercholesterolemia)
- Chronic kidney disease with elevated cardiovascular risk
Atorvastatin is also used in mixed dyslipidemia and familial combined hyperlipidemia. Dosing follows the product label and is titrated based on lipid targets and cardiovascular risk.
Pharmacokinetics
Absorption: Rapidly absorbed after oral administration; bioavailability is approximately 14% due to extensive first-pass metabolism.
Distribution: Highly protein-bound (≥98%); volume of distribution is approximately 380 L.
Metabolism: Extensively metabolized in the liver by CYP3A4 to active ortho- and para-hydroxylated metabolites that contribute to lipid-lowering activity. Atorvastatin and its metabolites account for approximately 70% of HMG-CoA reductase inhibition.
Excretion: Primarily eliminated in bile following hepatic and extrahepatic metabolism; less than 2% recovered in urine. Half-life is approximately 14 hours, but the half-life of inhibitory activity is 20–30 hours due to active metabolites.
Special considerations: No dosage adjustment needed in renal impairment. Use with caution in hepatic impairment. The long half-life allows once-daily dosing.
Adverse effects
Common
- Myalgia (muscle pain without CK elevation): 5–10%
- Headache
- Gastrointestinal upset (diarrhea, dyspepsia, nausea)
- Nasopharyngitis
- Arthralgia
Serious
- Myopathy and rhabdomyolysis: Muscle toxicity with elevated creatine kinase (CK), myoglobinuria, and potential acute kidney injury. Risk increased with higher doses, advanced age, hypothyroidism, renal impairment, and interacting drugs (especially CYP3A4 inhibitors, fibrates, niacin).
- Hepatotoxicity: Elevated transaminases (AST, ALT), typically dose-related and reversible. Baseline and periodic monitoring recommended.
- New-onset diabetes mellitus: Statins modestly increase risk of diabetes, particularly in patients with prediabetes or metabolic syndrome. Cardiovascular benefits outweigh this risk.
- Cognitive effects: Rare reports of memory loss or confusion, generally reversible.
- Hemorrhagic stroke: Slight increase in risk at very low LDL levels (<70 mg/dL), though overall stroke risk decreases.
Monitoring
Baseline hepatic function tests and CK if symptomatic. Recheck transaminases if clinically indicated. Counsel patients to report unexplained muscle pain, tenderness, or weakness immediately.
Contraindications and warnings
Absolute contraindications
- Active hepatic disease or unexplained persistent elevations of serum transaminases
- Pregnancy (Category X): statins reduce cholesterol synthesis essential for fetal development and may cause congenital anomalies
- Lactation: excreted in breast milk
- Hypersensitivity to atorvastatin or any component
Warnings and precautions
- Myopathy risk: Avoid or use cautiously with CYP3A4 inhibitors (e.g., azole antifungals, macrolides, protease inhibitors, cyclosporine, gemfibrozil). Risk increases with hypothyroidism, elderly patients, renal impairment, and alcohol abuse.
- Hepatic impairment: Use with caution; contraindicated in active liver disease.
- Hemorrhagic stroke: Consider risk vs. benefit in patients with prior hemorrhagic stroke.
- Immune-mediated necrotizing myopathy: Rare autoimmune myopathy presenting with proximal muscle weakness and markedly elevated CK that persists despite statin discontinuation. Associated with anti-HMGCR antibodies.
Pregnancy and lactation
Statins are teratogenic and absolutely contraindicated in pregnancy. Women of childbearing potential should use effective contraception. Discontinue atorvastatin if pregnancy is detected.
Drug interactions
Atorvastatin is metabolized by CYP3A4, making it susceptible to interactions with inducers and inhibitors of this enzyme.
Major interactions (increased myopathy risk)
- CYP3A4 inhibitors: Azole antifungals (itraconazole, ketoconazole), macrolide antibiotics (clarithromycin, erythromycin), HIV protease inhibitors, cyclosporine, diltiazem, verapamil, grapefruit juice
- Fibrates: Gemfibrozil (strongest interaction; avoid combination), fenofibrate (safer alternative if fibrate needed)
- Niacin: High-dose niacin increases myopathy risk
- Colchicine: Additive myopathy risk
Moderate interactions
- CYP3A4 inducers: Rifampin, phenytoin, carbamazepine, St. John's wort reduce atorvastatin levels and efficacy
- Warfarin: Statins may enhance anticoagulant effect; monitor INR
- Digoxin: Atorvastatin increases digoxin levels; monitor digoxin concentration
- Oral contraceptives: Atorvastatin increases ethinyl estradiol and norethindrone levels
Clinical management
Avoid strong CYP3A4 inhibitors when possible. If combination necessary, use the lowest effective atorvastatin dose and monitor closely for myopathy. Consider alternative statins not metabolized by CYP3A4 (e.g., pravastatin, rosuvastatin) in patients requiring interacting medications.
Clinical pearls
- High-intensity statin: Atorvastatin 40–80 mg is classified as high-intensity statin therapy (lowers LDL-C ≥50%) and is preferred for secondary prevention and high-risk primary prevention per ACC/AHA guidelines.
- Timing: Can be taken at any time of day with or without food, unlike some shorter-acting statins that are best taken in the evening.
- Grapefruit juice: Large amounts (>1 quart daily) inhibit CYP3A4 and increase atorvastatin levels, raising myopathy risk. Small amounts are generally acceptable.
- CK monitoring: Routine CK monitoring is not recommended in asymptomatic patients. Check CK only if patient develops muscle symptoms. Discontinue if CK >10 times upper limit of normal or if symptomatic myopathy occurs.
- Transaminase elevation: Mild elevations (<3× ULN) are common and often transient. Discontinue if persistent elevation >3× ULN.
- Diabetes risk: Statins increase HbA1c by approximately 0.1–0.2% and increase diabetes incidence by 10–12%. Cardiovascular benefits far outweigh this risk, and statin therapy should not be withheld.
- Coenzyme Q10: Some patients take CoQ10 supplements for statin-related myalgia, though evidence of benefit is limited.
- Fenofibrate combination: If a fibrate is needed with a statin (severe hypertriglyceridemia, mixed dyslipidemia), fenofibrate is preferred over gemfibrozil due to lower interaction risk.
- Exam tip: Statins upregulate LDL receptors and reduce LDL production. They do NOT reduce dietary cholesterol absorption (that's ezetimibe) and do NOT sequester bile acids (that's cholestyramine).
Statin side effects - LIVER ACHES: Liver toxicity (elevated transaminases), Increased blood glucose (diabetes risk), Vomiting/GI upset, Embryopathy (teratogenic), Rhabdomyolysis/myopathy, Amnesia (cognitive effects - rare), CK elevation, Hepatic contraindication, Enzyme CYP3A4 interactions, Statin-induced myalgia
Practice questions
1. A 58-year-old man with a history of myocardial infarction 6 months ago presents for follow-up. He is currently on atorvastatin 80 mg daily, aspirin, metoprolol, and lisinopril. He now complains of severe bilateral thigh pain and weakness that started 3 days ago. He denies fever or recent trauma. Physical examination reveals proximal muscle tenderness. Laboratory studies show creatine kinase 12,000 U/L (normal <200 U/L) and serum creatinine 2.1 mg/dL (baseline 1.0 mg/dL). Urinalysis shows 3+ blood with no RBCs on microscopy. What is the most appropriate next step in management?
2. A 52-year-old woman with hyperlipidemia, hypertension, and type 2 diabetes is being treated with atorvastatin 40 mg daily. She develops a vaginal yeast infection and is prescribed itraconazole by her primary care physician. Two weeks later, she presents with muscle pain and dark urine. Which of the following best explains the increased risk of statin toxicity in this patient?
3. A 35-year-old woman with familial hypercholesterolemia has been taking atorvastatin 80 mg daily for 2 years with good LDL cholesterol control. She now presents to the clinic stating that she is 8 weeks pregnant. Her physical examination is unremarkable. What is the most appropriate management of her atorvastatin therapy?
Frequently asked questions
How does atorvastatin work?
Atorvastatin competitively inhibits HMG-CoA reductase, the enzyme responsible for the rate-limiting step in cholesterol synthesis in the liver. This reduces intracellular cholesterol, causing hepatocytes to upregulate LDL receptors on their surface, which increases the clearance of LDL cholesterol from the bloodstream. The result is a significant reduction in plasma LDL cholesterol levels, typically 35–50% depending on the dose. Beyond lipid lowering, atorvastatin has pleiotropic anti-inflammatory and vascular stabilizing effects that contribute to reduced cardiovascular events.
What are the side effects of atorvastatin?
The most common side effects include myalgia (muscle pain), headache, and gastrointestinal symptoms like diarrhea and nausea. Serious adverse effects include myopathy and rhabdomyolysis (muscle breakdown with elevated creatine kinase, potentially leading to kidney injury), and hepatotoxicity with elevated liver enzymes. Atorvastatin modestly increases the risk of new-onset diabetes, particularly in predisposed individuals. Patients should report unexplained muscle pain, tenderness, or weakness immediately, as this may signal myopathy requiring drug discontinuation.
Is atorvastatin a controlled substance?
No, atorvastatin is not a controlled substance. It does not have abuse potential and is not regulated under the Controlled Substances Act. Atorvastatin is available by prescription only for the management of hyperlipidemia and cardiovascular risk reduction, but it is not classified as a controlled medication.
Can I drink grapefruit juice while taking atorvastatin?
Small amounts of grapefruit juice are generally considered acceptable, but large quantities (more than one quart daily) should be avoided. Grapefruit juice inhibits CYP3A4, the enzyme that metabolizes atorvastatin, leading to increased blood levels of the drug and a higher risk of adverse effects like myopathy. If you regularly consume grapefruit or grapefruit juice, discuss this with your healthcare provider, who may adjust your dose or consider an alternative statin less affected by this interaction.
Atorvastatin vs simvastatin — what is the difference?
Both atorvastatin and simvastatin are HMG-CoA reductase inhibitors (statins) that lower LDL cholesterol, but they differ in potency, half-life, and drug interactions. Atorvastatin is more potent and has a longer half-life (14 hours vs. 2–3 hours), allowing once-daily dosing at any time, whereas simvastatin is typically taken in the evening. Atorvastatin 40–80 mg is considered high-intensity therapy, while simvastatin is generally moderate-intensity. Both are metabolized by CYP3A4 and have similar interaction profiles, but simvastatin carries a higher risk of myopathy, particularly at the 80 mg dose, which is no longer routinely recommended.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: C10AA05
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.